180 related articles for article (PubMed ID: 36564637)
1. Censoring in the time trade-off valuation of worse-than-dead EQ-5D-5L health states: can a time-based willingness-to-accept question be the solution?
Liao M; Rand K; Yang Z; Hsu CN; Lin HW; Luo N
Qual Life Res; 2023 Apr; 32(4):1165-1174. PubMed ID: 36564637
[TBL] [Abstract][Full Text] [Related]
2. Valuation of the EQ-5D-5L with composite time trade-off for the German population - an exploratory study.
Ludwig K; von der Schulenburg JG; Greiner W
Health Qual Life Outcomes; 2017 Feb; 15(1):39. PubMed ID: 28219389
[TBL] [Abstract][Full Text] [Related]
3. Censoring Time Trade-off Values at 0 Versus at -1: How Does the Assumption for Worse-Than-Dead Time Trade-off Values Affect the Modeling of EQ-5D-5L Valuation Data?
Yang Z; Rand K; Luo N
Value Health; 2023 May; 26(5):685-693. PubMed ID: 36375679
[TBL] [Abstract][Full Text] [Related]
4. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set.
Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM
Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730
[TBL] [Abstract][Full Text] [Related]
5. How different are composite and traditional TTO valuations of severe EQ-5D-5L states?
Xie F; Pullenayegum E; Gaebel K; Bansback N; Bryan S; Ohinmaa A; Poissant L; Johnson JA
Qual Life Res; 2016 Aug; 25(8):2101-8. PubMed ID: 26875190
[TBL] [Abstract][Full Text] [Related]
6. Comparison of online and face-to-face valuation of the EQ-5D-5L using composite time trade-off.
Jiang R; Shaw J; Mühlbacher A; Lee TA; Walton S; Kohlmann T; Norman R; Pickard AS
Qual Life Res; 2021 May; 30(5):1433-1444. PubMed ID: 33247810
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan.
Shiroiwa T; Ikeda S; Noto S; Igarashi A; Fukuda T; Saito S; Shimozuma K
Value Health; 2016; 19(5):648-54. PubMed ID: 27565282
[TBL] [Abstract][Full Text] [Related]
8. A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada.
Xie F; Pullenayegum E; Gaebel K; Bansback N; Bryan S; Ohinmaa A; Poissant L; Johnson JA;
Med Care; 2016 Jan; 54(1):98-105. PubMed ID: 26492214
[TBL] [Abstract][Full Text] [Related]
9. Using Time Trade-Off Values to Estimate EQ-5D-Y Value Sets: An Exploratory Study.
Yang Z; Jiang J; Wang P; Wu J; Fang Y; Feng D; Xi X; Luo N
Value Health; 2023 Jul; 26(7):968-973. PubMed ID: 36921897
[TBL] [Abstract][Full Text] [Related]
10. Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States.
Burström K; Teni FS; Gerdtham UG; Leidl R; Helgesson G; Rolfson O; Henriksson M
Pharmacoeconomics; 2020 Aug; 38(8):839-856. PubMed ID: 32307663
[TBL] [Abstract][Full Text] [Related]
11. Re-revisiting the Utilities of Health States Worse than Dead: The Problem Remains.
Jakubczyk M
Med Decis Making; 2023; 43(7-8):875-885. PubMed ID: 37846095
[TBL] [Abstract][Full Text] [Related]
12. Preference heterogeneity in health valuation: a latent class analysis of the Peru EQ-5D-5L values.
Karim S; Craig BM; Tejada RA; Augustovski F
Health Qual Life Outcomes; 2023 Jan; 21(1):1. PubMed ID: 36593473
[TBL] [Abstract][Full Text] [Related]
13. Beyond 10-year lead-times in EQ-5D-5L: leveraging alternative lead-times in willingness-to-accept questions to capture preferences for worse-than-dead states and their implication.
Chang JA; Hsu CN; Ramos-Goñi JM; Luo N; Lin HW; Lin FJ
Eur J Health Econ; 2023 Dec; ():. PubMed ID: 38072877
[TBL] [Abstract][Full Text] [Related]
14. Testing "Pits" Time Trade-Off: Can Data Quality be Improved by Removing Death From Valuation of Health States?
Liao M; Yang Z; Rand K; Luo N
Value Health; 2024 May; ():. PubMed ID: 38795961
[TBL] [Abstract][Full Text] [Related]
15. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets.
Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A
Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577
[TBL] [Abstract][Full Text] [Related]
16. United States Valuation of EQ-5D-5L Health States Using an International Protocol.
Pickard AS; Law EH; Jiang R; Pullenayegum E; Shaw JW; Xie F; Oppe M; Boye KS; Chapman RH; Gong CL; Balch A; Busschbach JJV
Value Health; 2019 Aug; 22(8):931-941. PubMed ID: 31426935
[TBL] [Abstract][Full Text] [Related]
17. Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe.
Golicki D; Jakubczyk M; Graczyk K; Niewada M
Pharmacoeconomics; 2019 Sep; 37(9):1165-1176. PubMed ID: 31161586
[TBL] [Abstract][Full Text] [Related]
18. Dutch Tariff for the Five-Level Version of EQ-5D.
M Versteegh M; M Vermeulen K; M A A Evers S; de Wit GA; Prenger R; A Stolk E
Value Health; 2016 Jun; 19(4):343-52. PubMed ID: 27325326
[TBL] [Abstract][Full Text] [Related]
19. Cross-Attribute Level Effects Models for Modeling Modified 5-Level Version of EQ-5D Health State Values: Is Less Still More?
Yang Z; Rand K; Busschbach J; Luo N
Value Health; 2023 Jun; 26(6):865-872. PubMed ID: 36566885
[TBL] [Abstract][Full Text] [Related]
20. EQ-5D-5L Value Set for Slovenia.
Prevolnik Rupel V; Ogorevc M
Pharmacoeconomics; 2023 Nov; 41(11):1515-1524. PubMed ID: 37341959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
